EGFR and hepatocellular carcinoma: In the SEARCH trial, performed in treatment-naïve advanced HCC patients, however, sorafenib and EGFR inhibitor erlotinib combination did not fare better against placebo, a meaningful clinical response was observed with lenvatinib and EGFR inhibitor gefitinib combination in a small study in 12 lenvatinib-unresponsive patients [38,39].